Meridian Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Withdraws registration statement filed with the Securities and Exchange Commission for the proposed sale of 2 mil. shares of common stock, citing "unsettled market conditions affecting companies related to the health care industry." The Cincinnati immunodiagnostic firm's chairman, William Motto, said in a July 29 press release that the firm "was unwilling to sell shares at a price level which failed to recognize the company's record of growth and its expectations".
You may also be interested in...
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Dutch Supplements Firm Caught Buying Fake Instagram Followers
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: